Rezafungin (Rezzayo) for Invasive Candida Infections
Rezafungin (Rezzayo) for Invasive Candida Infections
June 24, 2024 (Issue: 1705)
The FDA has approved rezafungin (Rezzayo – Cidara/Melinta), an intravenous echinocandin antifungal, for
once-weekly treatment of candidemia and invasive
candidiasis (IC) in adults with limited or no alternative
options. It is the first new drug...more
- M Lyman et al. Notes from the field: transmission of panresistant and echinocandin-resistant Candida auris in health care facilities – Texas and the District of Columbia, January-April 2021. MMWR Morb Mortal Wkly Rep 2021; 70:1022. doi:10.15585/mmwr.mm7029a2
- PG Pappas et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1. doi:10.1093/cid/civ933
- F Lamoth. Novel therapeutic approaches to invasive candidiasis: considerations for the clinician. Infect Drug Resist 2023; 16:1087. doi:10.2147/idr.s375625
- GR Thompson III et al. Rezafungin versus caspofungin for treatment of candidemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial. Lancet 2023; 401:49. doi:10.1016/s0140-6736(22)02324-8
- JB Locke et al. Outcomes by Candida spp. in the ReSTORE phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis. Antimicrob Agents Chemother 2024; 68:e0158423. doi:10.1128/aac.01584-23
- GR Thompson III et al. Rezafungin versus caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: the STRIVE trial. Clin Infect Dis 2021; 73:e3647. doi:10.1093/cid/ciaa1380
- GR Thompson III et al. Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials. Lancet Infect Dis 2024; 24:319. doi:10.1016/s1473-3099(23)00551-0
- JB Locke et al. Characterization of in vitro resistance development to the novel echinocandin CD101 in Candida species. Antimicrob Agents Chemother 2016; 60:6100. doi:10.1128/aac.00620-16
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Rezafungin (Rezzayo) for Invasive Candida Infections
Article code: 1705d
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
